iSERA Lifesciences posts FY26 profit of ₹25.94 lakhs
The company reported its annual audited results, showing a strong finish in Q4 as it pivots into software and IT services.
What's new
- Annual revenue reached ₹120.20 lakhs in FY26.
- Q4 performance accounted for nearly all of the year's revenue, with ₹119.69 lakhs reported.
- Auditors issued an unmodified opinion on the standalone financial statements.
Why this matters
iSERA is transitioning from a period of minimal activity to generating revenue. While the numbers are small, the leap in the final quarter validates the shift toward software and IT services after the recent capital raise.
What we're watching
- Revenue consistency in the coming quarters.
- Use of funds from the ₹8.08 crore rights issue.
- Operational expenses as the business scales.
The full read
iSERA Lifesciences reported a net profit of ₹25.94 lakhs for FY26, more than doubling the ₹11.81 lakhs earned in the previous year. Revenue for the period hit ₹120.20 lakhs, an increase fueled entirely by a late-year surge. The company booked ₹119.69 lakhs in revenue and ₹34.68 lakhs in profit during Q4 alone. This performance follows the deployment of capital from an ₹8.08 crore rights issue, signaling early success in its move into the software and IT services space. The auditor confirmed the results with an unmodified opinion. For a company that previously operated with near-zero turnover, these figures represent a baseline of activity. The next test for iSERA is to maintain this revenue run-rate in the upcoming quarters.
Questions answered
- What drove the company's profit growth in FY26?
- Performance in the final quarter was the primary driver, contributing ₹119.69 lakhs in revenue and ₹34.68 lakhs in profit.
- What is the auditor's view on these results?
- The auditor provided an unmodified opinion on the standalone financial statements for the year.